drugset / Trial / NCT01541072

Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation

NCT01541072

Terminated 34 enrolled Centre Leon Berard Amgen · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to describe the kinetics of lymphocyte subsets reconstitution after growth factor administration, Pegfilgrastim versus Filgrastim in patients with B-cell malignant non-Hodgkin lymphoma treated with high-dose chemotherapy and autologous peripheral stem cell transplantation.

Timeline

Start
2012-02
Primary completion
2014-06
Completion
2014-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous
Comparator filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous